QuantuMDx Group Limited and Molbio Diagnostics Private Limited have signed a memorandum of understanding (MoU) to explore opportunities for joint working in infectious disease diagnostics, with an initial focus on genotypic drug resistance testing for those infected with tuberculosis.
QuantuMDx Group Limited and Molbio Diagnostics Private Limited have signed a memorandum of understanding (MoU) to explore opportunities for joint working in infectious disease diagnostics, with an initial focus on genotypic drug resistance testing for those infected with tuberculosis.
In addition, the two companies will also explore partnership opportunities around portfolio development and target sequencing.
QuantuMDx and Molbio announced the collaboration at the India-UK FutureTech Festival, a technology thought leadership summit, taking place in New Delhi and being co-hosted by the UK Department of International Trade and the Indian government.
QuantuMDx is a life science tools and diagnostics company based in Newcastle upon Tyne, United Kingdom and has designed and developed the Q-POC™ device, a rapid and portable DNA analyser. Molbio is a molecular diagnostics company based in Goa, India and has developed and commercialised the Truelab™ point-of-care Real Time PCR System and Truenat™ assays for various infectious diseases including tuberculosis.
The terms of the MoU enable both companies to investigate the complementary nature of their respective technologies, business operations and expertise, with the collective aim of improving healthcare for all, regardless of their socio-economic status or geographical location, through earlier diagnosis of disease.
Elaine Warburton OBE, Chief Executive Officer, QuantuMDx, said: “Molbio is a key player in the point-of-care molecular diagnostics market, established both in India and the rest of the world with its robust distributor network. Our companies share a similar ethos and commitment to ensuring accurate, accessible and affordable diagnostic solutions for all.
“Within this context, we are excited by the opportunity to collaborate with Molbio. We’re looking to maximise synergies and expand the capabilities of both companies, so we can complement, rather than compete against, each other and seek to address gaps in the provision of diagnostics, as partners.”
Chandrasekhar Nair, Director at Molbio Diagnostics, said: “QuantuMDx is at the forefront of innovation within the sector, developing two next-generation molecular diagnostic platforms (Q-POC™ and CAPTURE-XT®) which aim to expand point-of-care testing for all forms of TB, all ages and immune status. We are keen to work with them to explore mutual business opportunities, particularly focusing on assay development for multi-drug resistance TB, as it will be utilised on the Q-POC™ platform.
“We are also looking forward to supporting QuantuMDx in the development and implementation of a Q-POC™ distribution strategy for India and other key geographical markets.”
Elaine Warburton is currently taking part in the UK Department of International Trade Mission to India – Innovating for a Healthier World – encompassing visits by British healthcare innovators to health care providers and distributors in Bengaluru, New Delhi and Mumbai.
For more details: www.quantumdx.com and www.molbiodiagnostics.com
For media enquiries, please contact:
Debra Daglish, Marketing Communications Manager, QuantuMDx Group
Sumit Mitra, Marketing Manager, Molbio Diagnostics
